The days of maintaining paper records across the life sciences development and production pipeline are gone. Today’s regulatory requirements, not to mention the complexity of new treatments, requires organization that can only be provided electronically. However,...
The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace...
With registration now open for the October 24-28, 2022 Emerson Exchange conference in the Dallas, Texas area, I wanted to make sure you were aware that the Session Catalog is available for viewing.
In BioPhorum’s MES of the Future Manifesto, Sean and Kate Porter collaborated with other biomanufacturing leaders on requirements for future Manufacturing Execution Systems.
In an Australasian BioTechnology article, Facilities for a Strong Future, Emerson’s Michalle Adkins and Makarand Mujumdar share how pharmaceutical and biotech manufacturers can improve local capacity to meet the needs of the regions in which they operate.
There are four core pillars we look to address in order to support pharmaceutical and biopharmaceutical manufacturers in achieving line and facility efficiency goals.
Reliability of assets used in the manufacturing process is paramount for safe, efficient and effective operations. Unplanned asset failures, improper asset performance, poor maintenance planning, and untimely follow-through can cause shutdowns, under-utilized production equipment, deviations, or material/product losses.
For manufacturers in the Life Sciences industry, production challenges often occur in these four areas—production readiness, equipment reliability, personnel effectiveness and facility/line efficiency. In this post, I’ll focus on equipment reliability, and specifically, unplanned downtime.
In a presentation at the ACHEMA Pulse virtual conference this year, Emerson’s Alan Johnston shared how fast rollout of COVID vaccine manufacturing has changed the mindset of how quickly a new therapy can move from development to commercial manufacturing and ultimately to the consumer.
Accelerating vaccine development requires unprecedented flexibility in managing data. With increasing integration between product lifecycle management systems and software—like distributed control systems (DCS) and manufacturing execution systems (MES)—data, recipes, and processes can be digitally altered, shared, and used to scale across the lifecycle.
Technology has continued to advance and provide ways to assist pharmaceutical & biopharmaceutical manufacturers with production readiness. Improper set up and qualification of automation and information management production applications cause start-up and product changeover delays, as well as slow performance during production runs.
In a Pharmaceutical Processing World article, Emerson’s Ben Arriola and Zach Blum discuss technologies advancing vaccine development. It’s safe to say that there has never been a pharmaceutical effort so huge, fast, and successful as developing multiple vaccines for...
We invite you to follow us on Facebook, LinkedIn, Twitter and YouTube to keep up to date on all the latest news, events and innovations to help you take on and solve your toughest challenges.
Please do, Just link back to the post and send us a quick note so we can share your work. Thanks!
Our Global Community
The opinions expressed here are the personal opinions of the authors. Content published here is not read or approved by Emerson before it is posted and does not necessarily represent the views and opinions of Emerson.